

Upcoming Conferences

ESC Congress, August 28– September 1, 2010.
Stockholm, Sweden.

Rodman & Renshaw 12th Annual Healthcare conference,
September 12-15, 2010. New York, NY.

Resverlogix Analysts

Dr. Simos Simeonidis, Ph.D., Director and Senior Biotechnology Analyst, Rodman & Renshaw

Dr. David Martin, Ph.D., MBA, Analyst, Biotechnology & Healthcare, Dundee Securities Corporation

Mr. Claude Camiré, Biotech & Healthcare Analyst, Paradigm Capital

Market Opportunity

CVD is the leading killer of men and women in the industrialized world with over 18 million deaths reported in 2005 (WHO). One person will die every 30 seconds from CVD in the United States alone. The American Heart Association estimates that in 2007 roughly 80 million adults in the United States have one or more types of CVD. Drugs for the treatment of cardiovascular disease represent the largest pharmaceutical market opportunity in the world at US \$30-50 billion annually. There exists a huge unmet medical need for new cardiovascular therapies. Future estimates indicate that CVD mortality will increase by 90% by the year 2020 versus rates in 1990. The American Heart Association estimates the direct and indirect costs of CVD in the United States alone for 2007 are US \$431.8 billion.

About Resverlogix

Resverlogix Corp. (Toronto Stock Exchange: RVX) is a Canadian biotechnology company with a world lead in developing a new class of drugs for cardiovascular disease (CVD). **NexVas™ Plaque Regression (NexVas PR)**, is a novel technology platform with drugs that increase apolipoprotein A-I (ApoA-I) to reduce atherosclerosis (fatty plaque build-up in the arteries), which is the leading cause of CVD. Current drugs on the market only manage atherosclerosis burden but they have very limited or no effect on atherosclerosis regression. NexVas PR aims to manage and regress atherosclerosis. Resverlogix's lead ApoA-I drug **RVX-208** recently completed a Phase 2 clinical trial, named ASSERT which was conducted by Cleveland Clinic

Resverlogix Corp. trades on the Toronto Stock Exchange under the symbol RVX.

www.resverlogix.com

AGM Notice

September 9, 2010

2:00 pm Mountain time

Telus Convention Centre, Calgary, AB

Recent News

Scientific Data Presented at EAS Congress in Germany

June 22, 2010- Resverlogix Corp. announced that key scientific data was communicated in an oral presentation highlighting the novel features of the Company's lead drug RVX-208 at the European Atherosclerosis Society Congress (EAS) conference. The presentation titled "RVX-208 given orally raises plasma ApoA-I and HDL in human clinical trials," was presented by Dr. Norman Wong, MD, Chief Scientific Officer of Resverlogix.

"The data presented in Germany today further highlights that patients with low HDL/Apo-AI benefit most. For those patients in the highest risk category, subjects with low baseline HDL/Apo-AI, our data demonstrated that RVX-208 increased plasma levels of Apo-AI in the order of 13.25% compared to placebo. This data, combined with similar low baseline HDL/Apo A-I data analysis of the upcoming ASSERT trial data will further support the design of a very effective and efficient ASSURE trial," said Donald J. McCaffrey, President & CEO of Resverlogix.

Resverlogix Closes CDN \$10 Million Financing


June 22, 2010- Resverlogix announced that it has closed its previously announced prospectus offering of 3.1 million units at a price of CDN \$3.23 per Unit for gross proceeds of \$10 million. Each Unit was comprised of one common share of the Company and 0.4 of a common share purchase warrant. Each full warrant is exercisable at a price of CDN \$4.00 for a period of four years.

Resverlogix Closes CDN \$9.2 Million Financing

June 8, 2010- Resverlogix announced that it has closed its previously announced prospectus offering of 2.8 million units at a price of CDN \$3.30 per Unit for gross proceeds of \$9.2 million. Each Unit was comprised of one common share of the Company and 0.4 of a common share purchase warrant. Each full warrant is exercisable at a price of CDN \$4.00 for a period of four years.

Resverlogix Publishes Data in JACC

June 8, 2010- Resverlogix announced that it has collaborated with the Division of Cardiology at the Research Institute of the McGill University Health Centre (RI of the MUHC), to publish in the *Journal of American College of Cardiology (JACC)*, a report entitled 'RVX-208 A Small Molecule that Increases Apolipoprotein A-I and High Density Lipoprotein Cholesterol In Vitro and In Vivo'. This peer reviewed manuscript contains important data that describes the successful results of many studies detailing the actions of RVX-208, an orally active novel small molecule for the treatment of atherosclerosis.



HDL Molecule

© Resverlogix Corp.




Fact Sheet August 2010

About Atherosclerosis and ApoA-I

According to the World Health Organization, one person will die every 30 seconds from cardiovascular disease (CVD) in the United States alone. Atherosclerosis results from the build-up of fat and cholesterol in the artery wall, leading to a plaque that causes narrowing and hardening of the arteries, resulting in a loss of elasticity and function. Atherosclerosis is the underlying cause of CVD. ApoA-I is the key protein in high-density lipoprotein (HDL) also know as the “good cholesterol”. The beneficial role of ApoA-I continues to be established by demonstrating both the ability of reverse cholesterol transport (RCT) of arterial plaque and reduction of CVD risk. Thereby ApoA-I has secured the moniker, “the cardio-protective protein.” There is now a major paradigm shift in research and development of novel therapeutics that focus on ApoA-I production for the future management of CVD and atherosclerosis.

Resverlogix continues to build upon its world lead in this novel area of drug development. Current drugs on the market only manage atherosclerosis burden but they have very limited or no effect on atherosclerosis regression. NexVas PR aims to manage and regress atherosclerosis.

ATHEROSCLEROSIS DEVELOPMENT IN AN ARTERY



Investor Contact:

Theresa Kennedy

e. theresa@resverlogix.com

t. 604.538.7072